Your browser doesn't support javascript.
Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki, Koa; Chakraborty, Abhijit; Sur, Sanjiv.
  • Hosoki K; Department of Medicine, Immunology Allergy and Rheumatology, Baylor College of Medicine, Houston, Tex.
  • Chakraborty A; Department of Medicine, Immunology Allergy and Rheumatology, Baylor College of Medicine, Houston, Tex.
  • Sur S; Department of Medicine, Immunology Allergy and Rheumatology, Baylor College of Medicine, Houston, Tex. Electronic address: ssur@BCM.EDU.
J Allergy Clin Immunol ; 146(2): 285-299, 2020 08.
Article in English | MEDLINE | ID: covidwho-626243
ABSTRACT
The global pandemic caused by the newly described severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused worldwide suffering and death of unimaginable magnitude from coronavirus disease 2019 (COVID-19). The virus is transmitted through aerosol droplets, and causes severe acute respiratory syndrome. SARS-CoV-2 uses the receptor-binding domain of its spike protein S1 to attach to the host angiotensin-converting enzyme 2 receptor in lung and airway cells. Binding requires the help of another host protein, transmembrane protease serine S1 member 2. Several factors likely contribute to the efficient transmission of SARS-CoV-2. The receptor-binding domain of SARS-CoV-2 has a 10- to 20-fold higher receptor-binding capacity compared with previous pandemic coronaviruses. In addition, because asymptomatic persons infected with SARS-CoV-2 have high viral loads in their nasal secretions, they can silently and efficiently spread the disease. PCR-based tests have emerged as the criterion standard for the diagnosis of infection. Caution must be exercised in interpreting antibody-based tests because they have not yet been validated, and may give a false sense of security of being "immune" to SARS-CoV-2. We discuss how the development of some symptoms in allergic rhinitis can serve as clues for new-onset COVID-19. There are mixed reports that asthma is a risk factor for severe COVID-19, possibly due to differences in asthma endotypes. The rapid spread of COVID-19 has focused the efforts of scientists on repurposing existing Food and Drug Administration-approved drugs that inhibit viral entry, endocytosis, genome assembly, translation, and replication. Numerous clinical trials have been launched to identify effective treatments for COVID-19. Initial data from a placebo-controlled study suggest faster time to recovery in patients on remdesivir; it is now being evaluated in additional controlled studies. As discussed in this review, till effective vaccines and treatments emerge, it is important to understand the scientific rationale of pandemic-mitigation strategies such as wearing facemasks and social distancing, and implement them.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Asthma / Coronavirus Infections / Pandemics / Spike Glycoprotein, Coronavirus / Betacoronavirus / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: J Allergy Clin Immunol Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Asthma / Coronavirus Infections / Pandemics / Spike Glycoprotein, Coronavirus / Betacoronavirus / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: J Allergy Clin Immunol Year: 2020 Document Type: Article